Deep Genomics Stock
Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies.
About Deep Genomics Stock
The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.
Funding History
| November 2015 | $3.7M |
|---|---|
| September 2017 | $13.0M |
Management
Co-Founder
Hannes Bretschneider
Research Scientist & Engineer
Alice Gao
Co-Founder
Hui Yuan Xiong
Co-Founder
Andrew Delong
Co-Founder and CEO
Brendan Frey
Press
How Machine Learning Is Crafting Precision Medicine
Forbes - Feb, 11 2019
Khosla Backs AI Startup Creating New Class of Genetic Drugs
Wall Streets Journal - Sep, 25 2017
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Deep Genomics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
